DK175663B1 - Fremgangsmåde til opnåelse af beskyttende antigener mod Bordetalla-infektioner og toxiske processer - Google Patents
Fremgangsmåde til opnåelse af beskyttende antigener mod Bordetalla-infektioner og toxiske processer Download PDFInfo
- Publication number
- DK175663B1 DK175663B1 DK198901909A DK190989A DK175663B1 DK 175663 B1 DK175663 B1 DK 175663B1 DK 198901909 A DK198901909 A DK 198901909A DK 190989 A DK190989 A DK 190989A DK 175663 B1 DK175663 B1 DK 175663B1
- Authority
- DK
- Denmark
- Prior art keywords
- adenylate cyclase
- pertussis
- parapertussis
- preparations
- hly
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 20
- 208000015181 infectious disease Diseases 0.000 title claims description 8
- 230000008569 process Effects 0.000 title claims description 7
- 239000000427 antigen Substances 0.000 title description 5
- 108091007433 antigens Proteins 0.000 title description 5
- 102000036639 antigens Human genes 0.000 title description 5
- 230000001681 protective effect Effects 0.000 title description 5
- 231100000331 toxic Toxicity 0.000 title description 3
- 230000002588 toxic effect Effects 0.000 title description 3
- 102000030621 adenylate cyclase Human genes 0.000 claims abstract description 85
- 108060000200 adenylate cyclase Proteins 0.000 claims abstract description 85
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 241000588780 Bordetella parapertussis Species 0.000 claims abstract description 28
- 241000588832 Bordetella pertussis Species 0.000 claims abstract description 20
- 201000005702 Pertussis Diseases 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 12
- 102000000584 Calmodulin Human genes 0.000 claims abstract description 5
- 108010041952 Calmodulin Proteins 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 108010058846 Ovalbumin Proteins 0.000 claims abstract description 3
- 229940092253 ovalbumin Drugs 0.000 claims abstract description 3
- 230000001580 bacterial effect Effects 0.000 claims description 13
- 210000004072 lung Anatomy 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 7
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 241000588807 Bordetella Species 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000002054 inoculum Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 206010001889 Alveolitis Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 3
- 230000002497 edematous effect Effects 0.000 claims description 3
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 3
- 230000002008 hemorrhagic effect Effects 0.000 claims description 3
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 229940030156 cell vaccine Drugs 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 16
- 239000000284 extract Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 208000018150 Bordetella infection Diseases 0.000 description 2
- 241000917014 Bordetella pertussis 18323 Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000032376 Lung infection Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002480 immunoprotective effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000588851 Bordetella avium Species 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- SYUXAJSOZXEFPP-UHFFFAOYSA-N glutin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccccc3OC4OC(CO)C(O)C(O)C4O SYUXAJSOZXEFPP-UHFFFAOYSA-N 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- HQQSBEDKMRHYME-UHFFFAOYSA-N pefloxacin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 HQQSBEDKMRHYME-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP88400949A EP0338169B1 (en) | 1988-04-19 | 1988-04-19 | Method for obtaining protective antigens against bordetella infections and toxic processes |
| EP88400949 | 1988-04-19 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK190989D0 DK190989D0 (da) | 1989-04-19 |
| DK190989A DK190989A (da) | 1989-10-20 |
| DK175663B1 true DK175663B1 (da) | 2005-01-10 |
Family
ID=8200381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198901909A DK175663B1 (da) | 1988-04-19 | 1989-04-19 | Fremgangsmåde til opnåelse af beskyttende antigener mod Bordetalla-infektioner og toxiske processer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5595901A (es) |
| EP (2) | EP0338169B1 (es) |
| JP (1) | JP2999480B2 (es) |
| AT (1) | ATE140729T1 (es) |
| CA (1) | CA1341332C (es) |
| DE (1) | DE3855442T2 (es) |
| DK (1) | DK175663B1 (es) |
| ES (1) | ES2091186T3 (es) |
| GR (1) | GR3021331T3 (es) |
| PT (1) | PT90310B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2646776B1 (fr) | 1989-05-12 | 1994-06-03 | Pasteur Institut | Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella |
| US6338963B1 (en) | 1994-07-25 | 2002-01-15 | Neotherapeutics, Inc. | Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis |
| FR2728170A1 (fr) | 1994-12-15 | 1996-06-21 | Pasteur Institut | Vaccin de type acellulaire anti-bordetella |
| US6030625A (en) * | 1994-12-15 | 2000-02-29 | Institut Pasteur | Bordetella pertussis and Bordetella parapertussis strains |
| FR2736064B1 (fr) | 1995-06-30 | 1997-09-05 | Pasteur Institut | Epitopes protecteurs de l'adenyl cyclase-hemolysine(ac-hty). leur application au traitement ou a la prevention des infections par bordetella |
| AU3786299A (en) | 1998-05-04 | 1999-11-23 | Neotherapeutics, Inc. | Novel serotonin-like 9-substituted hypoxanthine and methods of use |
| US6288069B1 (en) | 1999-11-16 | 2001-09-11 | Neotherapeutics, Inc. | Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue |
| US6407237B1 (en) | 2001-02-21 | 2002-06-18 | Neotherapeutics, Inc. | Crystal forms of 9-substituted hypoxanthine derivatives |
| US6849735B1 (en) * | 2000-06-23 | 2005-02-01 | Merck Eprova Ag | Methods of synthesis for 9-substituted hypoxanthine derivatives |
| WO2002004452A2 (en) | 2000-07-07 | 2002-01-17 | Neotherapeutics, Inc. | Methods for treatment of disease-induced peripheral neuropathy and related conditions |
| US6759427B2 (en) | 2001-04-20 | 2004-07-06 | Spectrum Pharmaceuticals, Inc. | Synthesis and methods of use of tetrahydroindolone analogues and derivatives |
| US20030055249A1 (en) * | 2001-07-17 | 2003-03-20 | Fick David B. | Synthesis and methods of use of pyrimidine analogues and derivatives |
| US7462472B2 (en) * | 2001-11-02 | 2008-12-09 | The University Of Chicago | Methods and compositions relating to anthrax pathogenesis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412207D0 (en) * | 1984-05-12 | 1984-06-20 | Wellcome Found | Antigenic preparations |
| FR2606789B1 (fr) * | 1986-11-17 | 1991-05-31 | Pasteur Institut | Preparations d'adenylate cyclase purifiees, procede d'obtention de ces preparations et leurs applications biologiques |
| EP0338170A1 (en) * | 1988-04-19 | 1989-10-25 | Institut Pasteur | Immunoprotective antigenic protein against pathogenic bacteria |
| US5312749A (en) * | 1992-05-12 | 1994-05-17 | The United States Of America As Represented By The Secretary Of Agriculture | Industrial alkaline protease from shipworm bacterium |
-
1988
- 1988-04-19 ES ES88400949T patent/ES2091186T3/es not_active Expired - Lifetime
- 1988-04-19 DE DE3855442T patent/DE3855442T2/de not_active Expired - Fee Related
- 1988-04-19 EP EP88400949A patent/EP0338169B1/en not_active Expired - Lifetime
- 1988-04-19 AT AT88400949T patent/ATE140729T1/de not_active IP Right Cessation
- 1988-04-19 EP EP95111293A patent/EP0691348A1/en not_active Withdrawn
-
1989
- 1989-04-18 JP JP1096538A patent/JP2999480B2/ja not_active Expired - Fee Related
- 1989-04-19 CA CA000597153A patent/CA1341332C/en not_active Expired - Fee Related
- 1989-04-19 PT PT90310A patent/PT90310B/pt active IP Right Grant
- 1989-04-19 DK DK198901909A patent/DK175663B1/da not_active IP Right Cessation
-
1995
- 1995-06-06 US US08/466,882 patent/US5595901A/en not_active Expired - Fee Related
-
1996
- 1996-10-10 GR GR960402700T patent/GR3021331T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE3855442T2 (de) | 1997-03-06 |
| DE3855442D1 (de) | 1996-08-29 |
| JPH02131432A (ja) | 1990-05-21 |
| EP0338169A1 (en) | 1989-10-25 |
| PT90310B (pt) | 1994-09-30 |
| EP0691348A1 (en) | 1996-01-10 |
| ATE140729T1 (de) | 1996-08-15 |
| JP2999480B2 (ja) | 2000-01-17 |
| EP0338169B1 (en) | 1996-07-24 |
| GR3021331T3 (en) | 1997-01-31 |
| DK190989A (da) | 1989-10-20 |
| ES2091186T3 (es) | 1996-11-01 |
| PT90310A (pt) | 1989-11-10 |
| CA1341332C (en) | 2002-01-08 |
| DK190989D0 (da) | 1989-04-19 |
| US5595901A (en) | 1997-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0914153B1 (en) | Multivalent dtp-polio vaccines | |
| DK175663B1 (da) | Fremgangsmåde til opnåelse af beskyttende antigener mod Bordetalla-infektioner og toxiske processer | |
| US6399076B2 (en) | Acellular pertussis vaccines and methods of preparation thereof | |
| Guiso et al. | Bordetella adenylate cyclase is a virulence associated factor and an immunoprotective antigen | |
| US6696065B1 (en) | Acellular pertussis vaccines and methods of preparation thereof | |
| NO319013B1 (no) | Vaksine omfattende type I overflateantigener fra Staphylococcus epidermidis, samt hyperimmune globuliner og antistoff rettet mot type I-overflateantigenet. | |
| MXPA97008481A (es) | Vacunas acelulares de pertussis y metodos de preparacion de las mismas | |
| Foster et al. | Immunological role of Brucella abortus cell walls | |
| CA2049129A1 (en) | Haemophilus paragallinarum vaccine | |
| Brézin et al. | Protective effects of anti-Bordetella pertussis adenylate cyclase antibodies against lethal respiratory infection of the mouse | |
| John Roche et al. | Phase variation of Haemophilus influenzae lipopolysaccharide: characterization of lipopolysaccharide from individual colonies | |
| IE843174L (en) | Vaccine comprising m. bovis protease. | |
| EP0048881B1 (en) | Immunization of humans against enterotoxogenic infection by escherichia coli | |
| NO317148B1 (no) | Nye svekkede Pseudomonas aeruginosastammer, vaksiner, fremgangsmate for fremstilling derav og terapeutisk middel | |
| Petersen et al. | The cell mediated and humoral immune response to vaccination with acellular and whole cell pertussis vaccine in adult humans | |
| RU2533815C1 (ru) | Способ получения протективной белоксодержащей фракции бактерий | |
| WO1990011777A1 (en) | Preparation of unassembled pilus subunits and vaccines containing them | |
| EP0563288B1 (en) | Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines | |
| Salinas-Carmona et al. | Immunogenicity is unrelated to protective immunity when induced by soluble and particulate antigens from Nocardia brasiliensis in BALB/c mice | |
| KR970001707B1 (ko) | 약독화 녹농균주 cfcpa 50243을 이용한 녹농균 감염 예방 백신 | |
| KR970001709B1 (ko) | 약독화 녹농균주 cfcpa 70018을 이용한 녹농균 감염 예방 백신 | |
| MXPA99000184A (es) | Vacunas multivalentes de dtp-polio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |
Country of ref document: DK |